Background. The continuing increase of the prevalence of asthma in the world, the lack of the expected therapeutic effect of current programs, make this phenomenon to be studied. One of the main causes of asthma exacerbation and worsening of the prognosis in the children’s population are infectious diseases that occur in connection with steroid therapy used in the asthma treatment. Aim: to study the relationship of steroid therapy in asthmatic children with the occurrence of community-acquired pneumonia, that changes asthma symptoms in them. Materials and methods. 39 children aged 3-18 years old with atopic asthma who received corticosteroid therapy, were examined. All patients were divided into 4 groups: Group 1 – patients received inhaled corticosteroids for 2 years; Group 2 – for 3-5 years; Group 3 – for more than 5 years; Group 4 – patients with newly diagnosed asthma and a short course of corticosteroid therapy in the remission. Results. The frequency of community-acquired pneumonia was analyzed in all groups. Strong positive correlation between the duration of use of moderate and moderate/high dose inhaled corticosteroid therapy in asthmatic children for more than 2 years and the occurrence of community-acquired pneumonia with development of complications (pulmonary hypertension, pulmonary fibrosis, pulmonary bullae, bronchiectasis) in 48.7% them was revealed. Conclusions. Strong positive correlation between the duration of moderate and moderate/high dose inhaled corticosteroid therapy in asthmatic children for more than 2 years and the occurrence of community-acquired pneumonia in them was revealed, that necessitates the antibiotics to be included in the medication therapy of asthma.

Asthma remains one of the most important medical and social problems of current medicine. Despite significant approaches the increase in its incidence continues. 334 million people worldwide are affected by this chronic disease and more than 250 thousand die every year. Current asthma treatment methods arent useful to achieve asthma control in half of patients that associates with high risk of exacerbation of the disease. Modern asthma management requires a deep analysis of the factors responsible for the asthma progression and the development of exacerbations. The European Academy of Allergology and Clinical Immunology was held May 26-30, 2018 in Munich. The present publication sums up speeches of leading experts in the field of allergology and clinical immunology. Well-known experts in the field of diagnostics, treatment, prevention of bronchial asthma, modern views on the problem, a common pathology, which, despite considerable efforts, continues to grow, especially in the childrens population. The use of recent advances in molecular allergology, clinical immunology makes it possible to convincingly prove the heterogeneity of bronchial asthma, the need to use new diagnostic and therapeutic methods: biomarkers to detect pheno-endotypic diseases with the appointment of strictly targeted individualized treatment of patients with the results of new biologics. All attention was paid to the study of emerging and clinical trends of uncontrolled bronchial asthma, proposals for the use of new classification structures with indication of biological markers of each pheno-endotype of uncontrolled bronchial asthma were considered. A revised version of the GINA with the revision of therapeutic tactics, including in children, is presented. The latest EAACI Congress made a significant contribution to improving the diagnosis and effective treatment of bronchial asthma, which will allow treating patients with different clinical manifestations of this disease.